Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428678 | 0.91 | HPGD (0.51) | HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31428818 | 0.89 | RIPK1 (0.48) | HTR2CHPGDRIPK1MKNK1MKNK2 | |
| SCHEMBL31428449 | 0.87 | HPGD (0.53) | HPGDPLAURALDH1A1 | |
| SCHEMBL31429044 | 0.85 | HPGD (0.50) | HPGDRIPK1PLAURALDH1A1 | |
| SCHEMBL31428699 | 0.85 | HTR2C (0.53) | HTR2CHPGDKDM4EPLAURALDH1A1 | |
| SCHEMBL31428741 | 0.85 | CCNC (0.50) | HPGDRIPK1MKNK1MKNK2MEN1 | |
| SCHEMBL31428601 | 0.85 | KDM4E (0.47) | HPGDKDM4EALDH1A1 | |
| SCHEMBL31428588 | 0.84 | HPGD (0.52) | HPGDMEN1ALDH1A1KMT2A | |
| SCHEMBL31428870 | 0.83 | HPGD (0.51) | HPGDRIPK1MKNK1MKNK2MEN1 | |
| SCHEMBL31429043 | 0.81 | NTRK1 (0.49) | HPGDRIPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HTR2C 4858/4885HPGD 4233/4885KDM4E 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.